SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending following FDA approval of YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children. This landmark decision is driving widespread community discussion about its de-risking impact, significant revenue potential, and possible short squeeze, with many speculating on substantial price targets and a potential buyout by a larger pharmaceutical entity.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA CRYPTO) is trending due to its high-speed, compliance-first Layer 1 infrastructure, which boasts impressive transaction throughput. The community is actively discussing its potential as a "financial plumbing" solution for institutions, especially with its integration of a fiat anchor from Bridge (a Stripe company) now operational. Many view KTA as an undervalued asset for cross-chain settlement and regulated financial flows, positioning it as a compelling complementary play to established crypto and tech giants.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. is trending after federal regulators approved an emergency permit and granted interstate status for its Santa Ynez Pipeline System, shifting regulatory authority from California to federal oversight. This is widely seen as a game-changing event that could enable the company to finally move stored oil and potentially trigger a short squeeze. However, some investors remain cautious about possible state-level legal challenges or the potential for future equity offerings.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

YEE Crypto is experiencing a surge in attention, driven by a fiercely loyal community actively buying dips and declaring it a generational opportunity within the Ethereum ecosystem. The conversation centers on an unfolding 'prophecy,' strong bullish momentum, and comparisons to legendary meme coins, positioning YEE as a potential catalyst for significant growth.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is trending amid widespread community accusations of being a "scam" or "rugpull," with many investors expressing deep frustration over its recent performance. Sentiment is heavily bearish, with calls to sell and shift assets to other cryptocurrencies like XRP, though a smaller group sees current price levels as an opportune time for accumulation ahead of a potential rebound.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently seeing a surge in conversation and trading volume following reports of significant insider stock purchases, notably by Apple CEO and Nike board member Tim Cook. This move has ignited fervent debate among the community, with many interpreting it as a strong vote of confidence and a potential turning point for the struggling brand, while skeptics question its fundamental impact amidst ongoing performance concerns.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to promising preliminary Phase 3 open-label data indicating a significant reduction in breast cancer recurrence rates. The community is actively discussing the very high cost-to-borrow rates and a low share float, fueling strong short-squeeze speculation. This is compounded by significant insider buying from the CEO, leading to widespread anticipation of a major partnership or acquisition within the biotech sector.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a top trending stock after securing FDA approval for its oral Wegovy pill, marking a significant milestone as the first GLP-1 oral therapy for weight management. The community is buzzing with excitement over the convenience of a pill versus injections, anticipating a massive expansion of the obesity market and a competitive edge against rivals. Investors are looking for a substantial re-rating of the stock, believing this approval signals a new era of growth and market leadership.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is experiencing significant upward momentum, driven by positive regulatory developments, strategic divestitures, and key partnerships in wealth management and digital payments. This rally has sparked extensive community discussion, with many celebrating its strong performance and ongoing transformation plan, while others express caution due to its rapid ascent and overbought technical indicators. The positive sentiment is reinforced by strong earnings and analyst upgrades, positioning it as a notable performer within the broader financial sector.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is seeing heightened conversation following a recent US$20 million public offering aimed at funding its demonstration-scale plant. Enthusiastic investors highlight the company's graduation from Shell's GameChanger program and new partnerships as strong validation for its unique recycling technology, while skeptics warn of a "pump and dump" lacking revenue and view the valuation as unsustainable.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second quarter of 2026.</li><li>The company said that a single adverse event of new onset AF was reported in Part D of the trial but added that the investigator deemed it as not related to the study drug.</li><li>While Stifel believes the company’s updates still leaves questions on safety, Truist reiterated optimism for the drug’s potential in treating hypertrophic cardiomyopathy.</li></ul>Shares of Edgewise Therapeutics (EWTX) traded 20% higher on Wednesday morning after the company announced positive safety data from the ongoing multi-part mid-stage clinical trial of EDG-7500 in hypertrophic cardiomyopathy (HCM).Earlier this year, the company reported positive results from Part B and Part C 50 mg and 100 mg fixed dose cohorts of the trial in which EDG-7500 administration led to improvements in key HCM disease markers. Hypertrophic Cardiomyopathy (HCM) is a genetic heart condition where the heart muscle thickens, making it harder to pump blood out, stiffening the heart, and potentially causing irregular rhythms, often leading to fatigue, shortness of breath, chest pain, or fainting.<h2 class="st-heading-2">New Study Updates</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-completion-of-the-edg-7500-cirrus-hcm-phase-2-parts-b-and-c-and-favorable-interim-safety-results-from-the-ongoing-part-d-study-in-hypertrophic-cardiomyopathy-302649113.html">said</a> on Wednesday that it also evaluated a lower 25mg fixed dose in certain participants in Parts B and C and evidence of clinical activity was observed across key HCM disease markers. A favorable safety profile was observed with no clinically meaningful changes in left ventricular ejection fraction (LVEF) and no events of atrial fibrillation (AF), it added. &nbsp;The company also reported interim safety results from Part D of the study and said that EDG-7500 generally had a favorable safety profile and was well tolerated.“The safety profile observed with EDG-7500 to date, across both healthy volunteers and the CIRRUS-HCM trial, supports the potential use of EDG-7500 in diverse HCM patient populations,” the company said.The company, however, said that a single adverse event of new onset AF was reported in Part D of the trial but added that the investigator deemed it as not related to the study drug. The trial participant was not on active cardiac monitoring at the time and had a history of arrhythmias, including supraventricular tachycardia, the company said.Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second quarter of 2026. It is looking forward to starting a late-stage trial by 2026-end.<h2 class="st-heading-2">Experts Are Divided</h2>Stifel thinks the update still leaves questions on safety that'll take more than additional open-label data to disprove. The analyst is now looking forward to longer-term/controlled late-stage data.As per Stifel, the next big catalyst for the stock is data from the late-stage trial being conducted by the company for its drug Sevasemten in patients with Becker muscular dystrophy, a rare, X-linked genetic disorder causing progressive muscle weakness, mainly in males. The results from the trial are expected in the fourth quarter of 2026.Truist, meanwhile, kept a ‘Buy’ rating and $46 price target on Edgewise Therapeutics following the company's updates. Truist remains bullish on the opportunity for EDG-7500 in both obstructive HCM and non-obstructive HCM given signs of efficacy in both patient groups, the analyst told investors in a research note.H.C. Wainwright, which has a $42 price target and ‘Buy’ rating on Edgewise, sees the data reinforcing the drug’s potential for differentiation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EWTX rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/EWTX">EWTX stock</a> is down by 2% this year and by about 12% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/netflix-pushes-back-on-trc-capital-mini-tender-bid-at-below-market-price/cLesy0MREv0">Netflix Pushes Back On TRC Capital’s Mini-Tender Bid At Below-Market Price</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Edgewise Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 

Equity

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 


<ul class="summary-bullets"><li>Ramaco will repurchase shares over 24 months.</li><li>It intends to purchase shares with available funds.</li><li>Ramaco had signed an umbrella CRADA with U.S. Department of Energy to accelerate the discovery, mining, processing, and creation of rare earths</li></ul>Ramaco Resources shares were in the spotlight on Wednesday after its board authorized a share repurchase program of up to $100 million over 24 months, a sign of the firm's strong financial position, even after a sharp rally this year. The announcement sent its shares up more than 6% in premarket trading.The company intends to purchase shares under the repurchase program opportunistically, using available funds, ensuring sufficient liquidity to fund its capital development program.“With the closing of Ramaco's previously announced $600-plus million (before fees) in capital raises in the second half of 2025, we are well-positioned. We can now pursue opportunities to unlock value and maximize shareholder returns,” said Randall Atkins, Chairman and CEO of Ramaco.<h2 class="st-heading-2">Strong Demand For Rare Earths Bodes Well For Ramaco</h2>Beyond capital returns, investors are tracking Ramaco’s push into rare earth minerals.&nbsp; Demand for rare earth minerals has been surging in the United States and globally, as they have become crucial for the production of EV batteries, play a vital role in the global transition to clean energy, and enable advanced defense systems. According to a McKinsey report, global demand for rare earths is projected to triple by 2035. &nbsp;Ramaco earlier also signed an Umbrella Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Energy's ("DOE") National Energy Technology Laboratory ("NETL"), in a bid to accelerate the discovery, mining, processing, and creation of rare earths and critical minerals and materials at its Brook Mine in Sheridan, Wyoming.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around METC trended in “extremely bullish” territory amid “extremely high” message volume.<figure class="image"><img style="aspect-ratio:628/76;" src="https://news.stocktwits-cdn.com/METC_PNG_278c3de7e2.webp" alt="Retail sentiment around METC trended in “extremely bullish” territory amid “extremely high” message volume." width="628" height="76"></figure> Ramaco Resources' stock has surged more than 57% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Samples of rare-earth minerals from Baiyun'ebo or Bayan Obo mining district are on display at the Institute of Geology and Geophysics, Chinese Academy of Sciences (IGGCAS) on May 17, 2025, in Beijing, China. (Photo by VCG/VCG via Getty Images)

After A Sharp Rally In 2025, Ramaco Is Doubling Down With $100M Share Buyback

Ramaco’s CEO said that, with $600 million-plus (before fees) in capital raises in the second half of 2025, the firm is well-positioned to pursue opportunities to unlock value and maximize shareholder returns.

<ul class="summary-bullets"><li>Hympavzi was approved by the U.S. Food and Drug Administration (FDA) in October 2024 for routine prophylaxis in adults and adolescents aged 12 years and older with severe hemophilia A or B without inhibitors.</li><li>The patient who died had hemophilia A and inhibitors.</li><li>Pfizer is now actively gathering information to understand the circumstances surrounding the death and identify the cause.</li></ul>One of the patients enrolled in Pfizer’s trial of Hympavzi in people living with a bleeding disorder died earlier this month, the company said.The company said in a letter to the World Federation of Hemophilia (WFH) and National Bleeding Disorders Foundation (NBDF) that the patient suffered a fatal thrombotic stroke after a minor surgery on December 14.Hympavzi was approved by the U.S. Food and Drug Administration (FDA) in October 2024 for routine prophylaxis in adults and adolescents aged 12 years and older with severe hemophilia A or B without inhibitors. Pfizer is now studying Hympavzi in people living with hemophilia A or B irrespective of whether they have inhibitors.Hemophilia A and B are bleeding disorders, but some patients develop "inhibitors" that stop standard blood clotting factors replacement therapy from working, making bleeds harder to stop. The patient who died had hemophilia A and inhibitors.The patient participated in the active treatment phase of the parent study in 2022 prior to entering the long-term extension study in 2023, according to Pfizer.<h2 class="st-heading-2">Pfizer’s Next Moves</h2>Pfizer is now actively gathering information to understand the circumstances surrounding the death and identify the cause with the support of the trial investigator and an independent external Data Monitoring Committee. The drugmaker said that regulatory authorities and investigators have been informed.The World Federation of Hemophilia (WFH) and National Bleeding Disorders Foundation (NBDF) &nbsp;noted that thrombosis is an adverse event of special interest with Hympavzi due to the drug’s mechanism of action as a rebalancing agent that targets tissue factor pathway inhibitor (TFPI) to increase thrombin generation for clot formation.“The use of marstacimab (Hympavzi) should include close monitoring for symptoms of thrombosis and other adverse events, especially in surgical settings in combination with clotting factor concentrates or bypassing agents,” they <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://wfh.org/article/wfh-and-nbdf-statement-on-severe-adverse-event-with-marstacimab-rebalancing-agent-for-hemophilia/">said</a> in a statement.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PFE fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours while message volume fell from ‘extremely high’ to ‘normal’ levels.A Stocktwits user expressed disappointment over the stock trading in the red while major pharma stocks rallied.<stembedurl>https://www.stocktwits.com/Micheal_Pothead/message/639969189</stembedurl> <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> has dropped nearly 6% this year and by over 6% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/fjet-stock-takes-a-breather-post-massive-rally/cLepsN8REH7">FJET Stock Takes A Breather Post Massive Rally – Starfighters Space Releases 2026 Plans After Stock Market Debut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Confirms Death Of Patient Enrolled In Hemophilia Drug Study

The company said in a letter to the World Federation of Hemophilia (WFH) and National Bleeding Disorders Foundation (NBDF) that the patient suffered a fatal thrombotic stroke after a minor surgery on December 14. 

<ul class="summary-bullets"><li>The deal will increase Cipher’s development pipeline to 3.4 GW across eight sites.</li><li>The acquisition site is also suitable for high-performance computing, the company said.&nbsp;</li><li>Recently, Cipher Mining has been expanding into AI and HPC spaces due to high demand.</li></ul>Cipher Mining Inc. (<a href="https://stocktwits.com/symbol/CIFR">CIFR</a>) announced that it is acquiring a 200-megawatt (MW) site in Ohio, called “Ulysses,” which will expand its footprint beyond Texas.The acquisition includes 195 acres of land, secured capacity, and utility agreements. The site is expected to be connected with the power grid by the fourth quarter (Q4) of 2027, after which Cipher will gain access to PJM, the nation’s largest wholesale electricity market.The acquisition site is also suitable for high-performance computing (HPC) due to its size, energization timeline, diverse fiber-path availability, and proximity to a major metropolitan area, the company said.Shares of Cipher Mining are up about 0.6% on Tuesday at the time of writing.<h2 class="st-heading-2">AI And HPC Expansion</h2>The latest Ohio site acquisition will not only expand Cipher’s geographical impact but will also increase its development pipeline to 3.4 GW across eight sites. Before this deal, the company had a pipeline of about 3.2 GW that was prioritized for HPC.“Hyperscalers are driving unprecedented demand for large-scale sites,” said Tyler Page, CEO of Cipher Mining. “Leveraging our proven sourcing capabilities, Cipher is continuing to seize the opportunity to shape the future of high-performance computing infrastructure. This new site, in a new power market, gives us additional capacity to continue expanding our HPC hosting business while broadening our geographical footprint.”The crypto mining platform has been aggressively pushing into the artificial intelligence (AI) and HPC space. In November, the company secured a 10-year HPC <a href="https://stocktwits.com/news-articles/markets/equity/why-did-cipher-mining-stock-surge-12-pre-market-today/cLPAKNeREa2">colocation deal</a> with AI cloud company Fluidstack to provide 39 MW of critical IT load at its Barber Lake site in Texas. The deal is estimated to add about $830 million in revenue for Cipher over the first decade.Later that same month, Cipher announced a <a href="https://stocktwits.com/news-articles/markets/equity/cifr-stock-surges-on-5-5-billion-15-year-lease-agreement-with-aws/cL2N5WfR3zW">15-year lease agreement</a> with Amazon Web Services to deliver 300 MW of capacity in 2026, valued at nearly $5.5 billion.<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around Cipher Mining shares slid into the ‘bearish’ territory from ‘bullish’ a day ago. At the same time, message volume declined to ‘low’ from ‘normal’ levels at the time of writing.Shares of CIFR are up over 238% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Cipher Mining logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cipher Mining Expands Beyond Texas With 200 MW Ohio Site Acquisition

Cipher Mining’s acquisition of “Ulysses” includes 195 acres of land and secured capacity with utility agreements that will connect with the power grid by Q4 2027. 

<ul class="summary-bullets"><li>UBS cited Echostar’s pivot from a wireless operator to an investment company after its spectrum portfolio sales as a reason for a valuation change.&nbsp;</li><li>UBS also noted that EchoStar’s approximately 3% SpaceX stake represented a significant upside for the company.&nbsp;</li><li>Citi said that SpaceX’s potential $800 billion valuation could double the pre-tax cost basis of EchoStar’s stake.</li></ul>EchoStar Corp. (<a href="https://stocktwits.com/symbol/SATS">SATS</a>) shares were in focus on Tuesday after the company received two price target updates from UBS and Citi, both of which underscored the impact of its <a href="https://stocktwits.com/symbol/SPACEX">SpaceX</a> stake.UBS lowered EchoStar’s price target to $125 from $128 while maintaining a ‘Neutral’ rating on the shares, according to TheFly. And in a separate note, Citi raised EchoStar’s price target to $111 from $87 with a ‘Neutral’ rating, as seen in TheFly.<h2 class="st-heading-2">The SpaceX Impact</h2>UBS noted that EchoStar’s pivot from a wireless operator to an investment company after the sale of about 75%-80% of its spectrum portfolio for roughly $43 billion warranted a valuation shift. UBS assigned $11B to the remaining spectrum based on precedents, resulting in the revised price target.However, the firm added that the company’s 3% SpaceX stake, now implied at about $22B or roughly $65 per share assuming an $800 billion valuation, represented a significant upside versus prior marks. Meanwhile, Citi analyst Michael Rollins hiked EchoStar’s price target, citing recent reports that SpaceX’s upcoming public listing at an allegedly $800B could double the pre-tax value of the cost basis for its SpaceX shares that it would receive after its pending spectrum sales.<h2 class="st-heading-2">Spectrum Deals</h2>In September, EchoStar agreed to sell its AWS-4 and H-block spectrum licenses to SpaceX in a $17 billion cash-and-stock deal that would give the satellite company up to $8.5 billion in SpaceX stock. Some media reports have also suggested that SpaceX may go public through a reverse merger with Echostar.Apart from the SpaceX deal, EchoStar also agreed to sell about $23 billion worth of low-band and mid-band wireless spectrum to AT&amp;T in August. Together, the deals shift EchoStar’s long-term focus away from direct-to-device satellite constellations.<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around EchoStar shares slid into the ‘bearish’ territory from ‘neutral’ a day ago, while message volume declined to ‘normal’ from ‘high’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1302/145;" src="https://news.stocktwits-cdn.com/Echostar_sentiment_png_7388af44d4.webp" alt="On Stocktwits, retail sentiment around EchoStar shares slid into the ‘bearish’ territory from ‘neutral’ a day ago, while message volume declined to ‘normal’ from ‘high’ levels at the time of writing." width="1302" height="145"></figure>Meanwhile, retail sentiment for SpaceX slipped into the ‘neutral’ territory from ‘bullish’ a day ago, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1295/161;" src="https://news.stocktwits-cdn.com/Tesla_sentiment_png_b6d54d6740.webp" alt="Retail sentiment for SpaceX slipped into the ‘neutral’ territory from ‘bullish’ a day ago, while message volume remained at ‘high’ levels." width="1295" height="161"></figure>Shares of EchoStar are up over 378% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the EchoStar Corporation (Echo Star) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

EchoStar’s SpaceX Stake Is Driving UBS, Citi Price Target Revisions

UBS lowered EchoStar’s price target to $125 from $128 while Citi raised the firm’s price target to $111 from $87, according to TheFly.

<ul class="summary-bullets"><li>Instacart acquired Eversight in 2022 whose AI-powered software allows retailers to test customized pricing and promotions directly with their individual customers.</li><li>The company said on Monday that while retail partners will continue to set their own prices on Instacart and they may choose to vary the price of items on a store-by-store basis, Instacart will not support any item price testing services.&nbsp;</li><li>The company also said that the pricing tests were not dynamic pricing or surveillance pricing and added that they were never based on supply or demand, personal data, demographics, or individual shopping behavior.</li></ul> Instacart (<a href="https://stocktwits.com/symbol/CART">CART</a>) said on Monday that retailers will no longer be able to use artificial intelligence-driven pricing tests on its grocery delivery platform after it drew flak from customers and the federal trade commission.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.instacart.com/company/updates/ending-item-price-tests-on-instacart">said</a> that retailers will no longer be able to use Eversight technology to run item price tests on Instacart. Instacart acquired Eversight in 2022 whose AI-powered software allows retailers to test customized pricing and promotions directly with their individual customers. According to Instacart, several retailers rely on Eversight to optimize pricing including The Giant Company, Schnucks, and Kroger. Grocers who used Eversight have recorded revenue growth of 1-3%, according to the company.However, this caused shoppers to pay different prices for identical items from the same store.“We understand that the tests we ran with a small number of retail partners that resulted in different prices for the same item at the same store missed the mark for some customers. At a time when families are working exceptionally hard to stretch every grocery dollar, those tests raised concerns, leaving some people questioning the prices they see on Instacart. That’s not okay,” Instacart said. “Now, if two families are shopping for the same items, at the same time, from the same store location on Instacart, they see the same prices — period.”<h2 class="st-heading-2">New Pricing Rules</h2>Instacart said on Monday that while retail partners will continue to set their own prices on Instacart and they may choose to vary the price of items on a store-by-store basis, Instacart will not support any item price testing services.“We’ll continue working closely with partners to remove markups where possible and better align their online prices with their in-store prices,” the company said.The company also said that the pricing tests were not dynamic pricing or surveillance pricing and added that they were never based on supply or demand, personal data, demographics, or individual shopping behavior.<h2 class="st-heading-2">Eversight Draws Flak</h2>Earlier this month, Consumer Reports <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.consumerreports.org/money/questionable-business-practices/instacart-ai-pricing-experiment-inflating-grocery-bills-a1142182490/#:~:text=Many%20U.S.%20shoppers%20who%20order,Sprouts%20Farmers%20Market%2C%20and%20Target.">noted</a> that the AI-enabled pricing experiments on Instacart caused price differences of as much as 23% for identical products from one customer to the next. The report also said that Instacart’s algorithmic pricing experiments were found to be occurring through the platform at several of the nation’s biggest grocery retailers, including Albertsons, Costco, Kroger, Safeway, Sprouts Farmers Market, and Target.Following the investigation by Consumer Reports, Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/ftc-investigating-instacarts-ai-pricing-tool-source-says-2025-12-17/">reported</a> that the U.S. Federal Trade Commission is probing Instacart and seeking information about its Eversight pricing tool. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>CART shares traded 2% lower at the time of writing. On Stocktwits, retail sentiment around CART stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.CART stock has risen 8% this year and by about 6.5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-interim-trial-results-in-chemotherapy-induced-pain-fail-to-boost-investor-confidence/cLeF8WPREMu">DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Instacart Pulls Plug On AI-Driven Grocery Pricing Tests After Shopper Backlash And Regulatory Scrutiny

The company said that retailers will no longer be able to use Eversight technology to run item price tests on Instacart.

<ul class="summary-bullets"><li>The deal between Boeing and Anduril seeks to bridge the gap between existing short- and long-range air defense systems with a cost-effective solution.</li><li>Boeing received an Other Transaction Authority Project Agreement from the U.S. Army to develop the new midrange interceptor on December 5.</li><li>The Army plans to finalize a decision on companies to advance to the prototype stage in 2026.</li></ul>Boeing Co. (<a href="https://stocktwits.com/symbol/BA/">BA</a>) will team up with Anduril Industries, a rocket motor company, in the U.S. Army’s Integrated Fires Protection Capability (IFPC) Increment 2 Second Interceptor competition, Anduril announced on Thursday.Anduril will provide propulsion for Boeing’s offering in the U.S. Army competition.Boeing had bagged an Other Transaction Authority (OTA) Project Agreement from the U.S. Army to develop the new midrange interceptor on Dec. 5, 2025, to improve defenses against potential aerial threats.<h2 class="st-heading-2">Partnership Goals</h2>The deal between Boeing and Anduril seeks to bridge the gap between existing short- and long-range air defense systems with a cost-effective solution to counter low-flying, mid-range threats, including cruise missiles and militarized drones.Anduril’s Senior Vice President Burhan Muzaffar said the deal with Boeing will deliver a scalable rocket motor capability for the U.S. Army, strengthening the industrial base and providing warfighters with reliable, modern capabilities.“This partnership underscores our commitment to forming innovative, disruptive, and agile industry teams that deliver new capabilities to warfighters sooner,” said Bob Ciesla, Vice President, Boeing Precision Engagement Systems. “We’re confident that this partnership will result in a novel solution that helps meet the Army’s evolving air defense needs.”According to Anduril, the Army expects the interceptors to improve existing systems, with plans to finalize a decision on companies to move forward to the prototype stage in 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BA stock remained in ‘bearish’ territory over the past day, and message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:1299/159;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_18_at_10_34_44_PM_png_2fad72cf05.webp" alt="On Stocktwits, retail sentiment around BA stock remained in ‘bearish’ territory over the past day, and message volume stayed at ‘low’ levels." width="1299" height="159"></figure>One user believes 2026 will be glorious for Boeing.<stembedurl>https://stocktwits.com/Footbal888/message/639583231</stembedurl>Shares of Boeing are up over 21% over the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Boeing logo is seen at the International Defence Industry Exhibition in Kielce, Poland, on September 2, 2025.

Boeing Stock In Spotlight On Anduril Partnership — What’s The Deal About?

Boeing is partnering with Anduril Industries for a U.S. Army interceptor bid wherein the latter will provide rocket motors.

Boeing Stock In Spotlight On Anduril Partnership – What’s The Deal About?

<ul class="summary-bullets"><li>Pfizer provides Covid vaccine called Comirnaty in addition to an antiviral medication used to treat COVID-19 called Paxlovid.</li><li>In 2026, the company expects the revenue to fall further or stay at 2025 levels within the range of $59.5 to $62.5 billion, owing to Covid product sales falling further to about $5 billion.</li><li>The company now expects earnings per share of about $3 to $3.15 for the current financial year and expects it to fall further down to $2.8-$3 in the financial year 2026.</li></ul>Pfizer shares fell about 5% on Tuesday, on pace for their worst session in over eight months, after BofA lowered its price target following the company’s updated guidance on waning Covid-19 product demand.The company now expects full year 2025 guidance of about $62 billion, to the lower end of its previous guidance of $61 to $64 billion and below an analyst estimate of $62.52 billion. Revenue from the company’s Covid-19 products is expected to be $6.5 billion. &nbsp;Pfizer provides Covid vaccine called Comirnaty in addition to an antiviral medication used to treat COVID-19 called Paxlovid. In the third quarter, Paxlovid and Comirnaty saw revenues in the quarter down by 55% and 19%, respectively, on a total basis as Covid-19 infections continue to drop.<h2 class="st-heading-2">Analyst Take</h2>BofA analyst Jason Gerberry subsequently lowered its price target on Pfizer to $27 from $28 while retaining a ‘Neutral’ rating on the shares. The analyst highlighted that the company is now looking to progress its obesity pipeline as Covid product demand falters.Pfizer <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ceo-sees-metsera-drugs-hit-market-as-early-as-2028-after-completing-acquisition-report/cLP9fAwREE9">acquired</a> obesity drugmaker Metsera for up to $86.25 per share in November after a bidding war with Danish drugmaker Novo Nordisk. Pfizer scrapped its own obesity drug candidate, Danuglipron, earlier this year, citing risks of liver enzyme elevations, leaving it with no in-house obesity drug candidate. The company expects Metsera’s MET-097i, a monthly injectable GLP-1, to be market-leading. The experimental drug is about to begin late-stage development.“Following the recent closing of our Metsera acquisition, our new exclusive global collaboration and license agreement with Yao Pharma and other Pfizer programs that include our GIPR antagonist candidate, we have a robust and diverse obesity portfolio,” CEO Albert Bourla said on Tuesday. “We plan to move quickly in 2026 to advance about 15 programs with many of them being phase 3 studies just for this program.”<h2 class="st-heading-2">Looking Further Ahead</h2>In 2026, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides">expects</a> the revenue to fall further or stay at 2025 levels within the range of $59.5 to $62.5 billion, owing to Covid product sales falling further to about $5 billion and loss of exclusivity on certain products creating a negative impact of about $1.5 billion. Wall Street, on average, expects FY26 revenue of about $61.68 billion, to the top end of current guidance range.The company now expects earnings per share of about $3 to $3.15 for the current financial year and expects it to fall further down to $2.8-$3 in financial year 2026, below an analyst estimate of $3.06. Pfizer’s recent acquisition of Metsera is further expected to increase research and development expenses to $10.5-$11.5 billion from $10 to $11 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PFE rose from ‘bearish’ &nbsp;to ‘bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user dismissed the new update from the company highlighting that the downside is minimal.<stembedurl>https://www.stocktwits.com/jjflanders/message/639319453</stembedurl>Yet another called for a CEO replacement.<stembedurl>https://www.stocktwits.com/PFElinepfrenzy1990/message/639309007</stembedurl><a href="https://stocktwits.com/symbol/PFE">PFE stock</a> fell 5% this year and by 1% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-aldeyra-therapeutics-stock-surging-after-fda-delayed-its-dry-eye-drug-decision/cLeJL0aREpd">Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Pfizer Stock On-Track For Worst Day In Over 8 Months As BofA Flags Faster Covid-19 Product Erosion

The company now expects full year 2025 guidance of about $62 billion, to the lower end of its previous guidance of $61 to $64 billion and below an analyst estimate of $62.52 billion.

Zootopia 2-themed installations at a pop-up store draw a child at Guomao shopping mall on December 2, 2025 in Beijing, China. (Photo by Zhang Xiangyi/China News Service/VCG via Getty Images)

Disney Stock Rises As ‘Zootopia 2’ Becomes Second Film This Year To Cross $1B Mark At The Global Box Office

According to Disney, the box office success has also reignited interest in the franchise, resulting in record viewership of Zootopia and Zootopia+ on Disney+. 

<ul class="summary-bullets"><li>Goldman Sachs increased Rivian’s price target to $16 from $13 while maintaining a ‘Neutral’ rating, citing confidence in new car updates.</li><li>Needham revised the automaker’s price target upwards to $23 from $14 and reiterated a ‘Buy’ rating.&nbsp;</li><li>Meanwhile, RBC Capital maintained its ‘Sector Perform’ rating and reaffirmed the $14 price target.</li></ul>Rivian Automotive Inc. (RIVN) shares rallied on Friday after Goldman Sachs and Needham raised their price targets on the electric vehicle company.Goldman Sachs raised the price target on Rivian to $16 from $13 while maintaining a ‘Neutral’ rating, according to TheFly. Needham increased its price target on the firm to $23 from $14 and reiterated a ‘Buy’ rating.The upgrades come after Rivian’s AI and autonomy event in California, where the automaker <a href="https://stocktwits.com/news-articles/markets/equity/rivian-unveils-in-house-ai-chip-to-replace-nvidia-and-challenge-tesla-in-the-autonomy-race/cLIx1TuREnx">announced</a> the development of its own proprietary silicon chip to replace Nvidia’s and its latest computer model, among other updates.Shares of <a href="https://stocktwits.com/symbol/RIVN/">RIVN</a> surged over 17% during market hours at the time of writing.Meanwhile, RBC Capital maintained its ‘Sector Perform’ rating and reiterated the $14 price target after the event.<h2 class="st-heading-2">Analyst Takes</h2>Goldman Sachs said it revised Rivian’s target upwards because it views the new car updates announced at the event as a platform for high-margin software, with future opportunities in advanced autonomy, third-party integrations, and potentially broader licensing.Needham’s rationale for its upgrade is its increased confidence in Rivian following its vertical integration announcement that would allow for fuller control, faster learning, and feature iterations across driver interface and autonomy technology, resulting in "durable competitive advantage", as cited in TheFly.However, RBC said that while Autonomy+ could potentially boost margins, it would still risk low take-rates sans an eyes-off solution. The firm also expressed concerns about the lack of clarity on Rivian’s liquidity concerns and R2/R3 profitability.<h2 class="st-heading-2">The Big Reveal</h2>In Thursday’s event, the company announced the development of a custom chip called RAP1 or Rivian Autonomy Processor 1, which would aid the automaker in achieving level 4 vehicle autonomy. So far, Rivian’s older car system employed Nvidia Orin chips.This chip will power Rivian’s third-generation compute module, the Gen 3 Autonomy Computer, which the company said would achieve 1600 sparse INT8 TOPS (trillion operations per second). This will enable the new system to process five billion pixels per second.In addition, the company said it planned to launch an Autonomy+ subscription in early 2026 for its next-gen customers. The software update would introduce universal hands-free driving for its customers, priced at $49.99 per month or a one-time price of $2,500.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, RIVN was among the top trending stocks on Friday morning. The retail sentiment around RIVN jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1281/148;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_at_9_45_55_PM_png_2675db84ad.webp" alt="Stock sentiment and message volume on Stocktwits." width="1281" height="148"></figure>One Stocktwits user said they would hold the stock even though some others might book a profit on the price rise.<stembedurl>https://stocktwits.com/Gusstastic/message/639008212</stembedurl>Another user commented that this wasn’t a shorts event but a result of people just realizing Rivian’s potential to become the most sought-after affordable car brand in the West.<stembedurl>https://stocktwits.com/Johamfly/message/639007785</stembedurl>Shares of RIVN are up over 42% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Rivian EVs are parked at the Rivian Venice Hub on November 13, 2024 in Venice, California. (Photo by Mario Tama/Getty Images)

Rivian Stock Rallies Post Needham, Goldman Price Target Hikes Following AI & Autonomy Day

Rivian received two price target upgrades, from Goldman Sachs and Needham, following multiple announcements at its AI and autonomy event. 

AVUS
American Century ETF Trust - Avantis U.S. Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AVUS News

AVUSAmerican Century ETF Trust - Avantis U.S. Equity ETF